SAN DIEGO--(BUSINESS WIRE)--Prominex, Inc., a molecular diagnostic company focused on point-of-care infectious disease testing, today announces completion of its Series A-1 financing, raising $4 million from Casdin Capital LLC and its founding CEO. The Series A-1 financing will provide funding to advance the development of its infectious disease assays and commence an instrument development partnership with Invetech, a global leader in point-of-care instrument design and development.
Prominex’s Founder and CEO Paul Thomas commented, “Our Validex System delivers a 5-minute sample-to-answer molecular test result that will enable a broad spectrum of point-of-care testing from simple screening to more complex syndromic panel assays. We believe our Validex System holds significant promise to improve patient care and outcomes in time-critical clinical situations and to realize significant cost savings by optimized patient management and triage of patients to the most appropriate care setting.”
About Prominex
Prominex was founded in 2016 with a primary focus on the development of molecular diagnostic assays for point-of-care infectious disease testing. The novel molecular amplification and waveguide detection technologies incorporated into our Validex System enables the development of ultrafast, accurate, easy-to-use, highly multiplexed, and low-cost molecular diagnostic assays. For more information, visit www.Prominex.com.
